

Table S2. The known SULT1A1 inhibitor dichloro-p-nitrophenol (DCNP) completely abrogates the activity of **1** (NSC 773097). Cell lines exhibiting less than 50% growth in response to 1  $\mu$ M of compound **1** are in bold.

Panel	Cell name	Percent Growth		
		1 $\mu$ M Cmpd <b>1</b>	10 $\mu$ M DCNP	Cmpd <b>1</b> + DCNP
Leukemia	CCRF-CEM	91	106	107
	HL-60(TB)	99	96	99
	K-562	96	112	95
	MOLT-4	94	96	94
	RPMI-8226	98	110	101
	SR	95	103	84
Non-Small Cell Lung Cancer	A549/ATCC	88	96	107
	EKVX	108	124	98
	HOP-62	88	106	106
	HOP-92	105	112	107
	<b>NCI-H226</b>	<b>-26</b>	<b>97</b>	<b>98</b>
	NCI-H23	111	110	106
	NCI-H322M	127	124	109
	NCI-H460	87	102	105
	NCI-H522	88	88	86
Colon Cancer	COLO 205	97	115	111
	HCC-2998	101	100	105
	HCT-116	89	103	100
	HCT-15	102	110	103
	HT29	92	102	110
	KM12	107	112	98
	SW-620	95	98	103
	CNS Cancer	SF-268	109	109
SF-295		98	113	94
SF-539		108	108	103
SNB-19		106	97	109
SNB-75		109		92
U251		96	98	105
Melanoma	LOX IMVI	110	101	101
	MALME-3M	116	114	96
	M14	106	99	104
	MDA-MB-435	112	113	106
	SK-MEL-2	99	109	80
	SK-MEL-28	113	106	113
	SK-MEL-5		95	
	UACC-257	90	90	121
	<b>UACC-62</b>	<b>43</b>	<b>91</b>	<b>109</b>
Ovarian Cancer	IGROV1	78	111	113
	OVCAR-3	103	113	100
	OVCAR-4	105	121	103
	<b>OVCAR-5</b>	<b>-3</b>	<b>115</b>	<b>109</b>
	OVCAR-8	116	99	126
	NCI/ADR-RES	107	105	103
	SK-OV-3	102	110	106
Renal Cancer	786-0	101	95	92
	<b>A498</b>	<b>-93</b>	<b>92</b>	<b>97</b>
	ACHN	111	110	109
	CAKI-1	104	108	104
	RXF 393	107	104	108
	SN12C	104	100	112
	<b>TK-10*</b>	<b>-100</b>	<b>105</b>	<b>108</b>
	UO-31	105	85	92
	Prostate Cancer	PC-3	93	102
DU-145		106	118	105
Breast Cancer	MCF7	68	98	93
	MDA-MB-231/ATCC	111	98	107
	HS 578T	101	101	106
	BT-549	113	97	110
	T-47D	61	101	99
	<b>MDA-MB-468</b>	<b>5</b>	<b>104</b>	<b>91</b>
	Mean	87	104	103

\*Note: Strong activity for compound **1** alone in TK-10 is most likely experimental noise, as growth in two separate NCI-60 five-dose assays reached no lower than 49% at 1  $\mu$ M.